Said Dermime|Said Dermine

Said Dermime|Said Dermine

Hamad Medical Corporation - Doha / Qatar
Medical and Health Sciences / Immunology
AD Scientific Index ID: 4698666
person_outline Said Dermime|Said Dermine's MOST POPULAR ARTICLES
1-) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic … H Ghebeh, S Mohammed, A Al-Omair, A Qattant, C Lehe, G Al-Qudaihi, ... Neoplasia 8 (3), 190-198, 2006 6472006
2-) Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccinesQ Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ...Annals of medicine 54 (1), 524-540, 20224312022
3-) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cellsJ Molldrem, S Dermime, K Parker, YZ Jiang, D Mavroudis, N Hensel, ...4271996
4-) NY-ESO-1 based immunotherapy of cancer: current perspectivesR Thomas, G Al-Khadairi, J Roelands, W Hendrickx, S Dermime, ...Frontiers in immunology 9, 947, 20184132018
5-) FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapyH Ghebeh, E Barhoush, A Tulbah, N Elkum, T Al-Tweigeri, S DermimeBMC cancer 8, 1-12, 20082892008